Samuel Wei Liu       Art Unit 1653         NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATION CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCI DISCLOSURES         Applicant must file the items indicated below within the time period set the Office action to which is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained of provisions of 37 CFR 1.136(a)).         The nucleotide and/or amino acid sequence disclosure contained in this application does not co the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following re of the requirements of such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825. Al oG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1993, see the final rule attention is directed to the final rulemaking notice published at 65 FR 18230 (May 1, 1990), oG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1993, see the final rule attention is directed to the final rulemaking notice published at 65 FR 18230 (May 1, 1990), attention is directed to the final rulemaking notice published at 65 FR 18230 (May 1, 1990), attention is directed to the final rulemaking notice published at 65 FR 18230 (May 1, 1990), attention is directed to the final rulemaking notice published at 65 FR 18230 (May 1, 1990), attention is directed to the final rulemaking notice published at 65 FR 18230 (May 1, 1990), attention is directed to the final rulemaking notice published at 65 FR 18230 (May 1, 1990), attention is directed to the final rulemaking notice published at 65 FR 18230 (May 1, 1990), attenting as required by 37 C.F.R. 1.821(c).         2       This application does not comply with the requirements of 37 C.F.R. 1. 821(e).         3. A copy of the "Sequence Listing" in computer readable form has been submitted. H	Notice to Comply	P 0 7 200 - Application No. 09673274		
<ul> <li>NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATION CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES</li> <li>Applicant must file the items indicated below within the time period set the Office action to which is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained to provisions of 37 CFR 1.136(a)).</li> <li>The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements of 37 C.F.R. 1.821 - 1.825 for the following reattention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), a ditention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), a cod 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rule notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).</li> <li>2. This application does not contain, as a separate part of the disclosure on paper copy, a "S Listing" as required by 37 C.F.R. 1.821(c).</li> <li>3. A copy of the "Sequence Listing" in computer readable form has not been submitted as readiated on the attached copy of the marked -up "Raw Sequence Listing."</li> <li>5. The computer readable form that has been filed with this application has been found to be rand/or unreadable is indicated on the attached CRF Diskette Problem Report. A Substitute creadable form must be submitted as required by 37 C.F.R. 1.821(e).</li> <li>7. Other: the specification contains peptide sequences without the corresponding SECOS (see Quayle Action). Applicants are required to comply with requirements for patent application insubstitute paper copy of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).</li> <li>7. Other: the specification contains peptide sequences without the corresponding SECOS (see Quayle Action). Applicants are required to comply with requirements for patent application thas besen file</li></ul>		E.	Examiner Samuel Wei Lin	1 . I
DISCLOSURES         Applicant must file the items indicated below within the time period set the Office action to which is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained of provisions of 37 CFR 1.136(a)).         The nucleotide and/or amino acid sequence disclosure contained in this application does not control the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reduce the requirements of such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reduce published at 55 FR 18230 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rule notice published at 65 FR 19820 (June 1, 1998) and 1211 OG 82 (June 23, 1998).         □       2. This application does not contain, as a separate part of the disclosure on paper copy, a "S Listing" as required by 37 C.F.R. 1.821(c).         □       3. A copy of the "Sequence Listing" in computer readable form has not been submitted as red 37 C.F.R. 1.821(e).         □       4. A copy of the "Sequence Listing" in computer readable form has been submitted. However content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.821(e).         □       5. The computer readable form that has been filed with this application has been found to be and/or unreadable form must be submitted as required by 37 C.F.R. 1.821(e).         □       6. The paper copy of the "Sequence Listing" is not the same as the computer readable form or "Sequence Listing" as required by 37 C.F.R. 1.821(e).         □       7. Other: the specification contains peptide sequences without the corresponding SEC orequence Listing" as required by 37 C.F.R. 1.821(e). <td>CE TO COMPLY WITH</td> <td>REQUIRI</td> <td></td> <td></td>	CE TO COMPLY WITH	REQUIRI		
<ul> <li>Provisions of 37 CFR 1.136(a)).</li> <li>The nucleotide and/or amino acid sequence disclosure contained in this application does not containe requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following regime is directed to the final rulemaking notice published at 53 FR 18230 (May 1, 1990), a tentition is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990).</li> <li>Q G 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rule notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).</li> <li>2. This application does not contain, as a separate part of the disclosure on paper copy, a "S Listing" as required by 37 C.F.R. 1.821(c).</li> <li>3. A copy of the "Sequence Listing" in computer readable form has not been submitted as red 37 C.F.R. 1.821(e).</li> <li>4. A copy of the "Sequence Listing" in computer readable form has been submitted. However content the computer readable form that has been filed with this application has been found to be and/or unreadable as indicated on the attached CQF Diskette Problem Report. A Substitute or readable form must be submitted as required by 37 C.F.R. 1.821(e).</li> <li>5. The computer readable form that has been filed with this application has been found to be and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute or readable form must be submitted as required by 37 C.F.R. 1.821(e).</li> <li>6. The paper copy of the "Sequence Listing" is not the same as the computer readable from or "Sequence Listing" as required by 37 C.F.R. 1.821(e).</li> <li>7. Other: the specification contains peptide sequences without the corresponding SEt OS: (see Quayle Action). Applicants are required to comply with requirements for patent application the specification.</li> <li>A ninitial or substitute computer readable form (CRF) copy of the "Sequence Listing".</li> <li>An initial or substitute paper copy of the "Sequence Listing", as well</li></ul>	AINING NUCLEOTIDE	SEQUEN	ICE AND/OR AMINO	ACID SEQUENCE
<ul> <li>I. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Application is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), a notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).</li> <li>I. This application does not contain, as a separate part of the disclosure on paper copy, a "S Listing" as required by 37 C.F.R. 1.821(c).</li> <li>3. A copy of the "Sequence Listing" in computer readable form has not been submitted as red 37 C.F.R. 1.821(e).</li> <li>4. A copy of the "Sequence Listing" in computer readable form has been submitted. However content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.821(e).</li> <li>5. The computer readable form does not comply with the requirements of 37 C.F.R. 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."</li> <li>5. The computer readable form that has been filed with this application has been found to be and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute of "Sequence Listing" as required by 37 C.F.R. 1.821(e).</li> <li>6. The paper copy of the "Sequence Listing" is not the same as the computer readable from or "Sequence Listing" as required by 37 C.F.R. 1.821(e).</li> <li>7. Other: the specification contains peptide sequences without the corresponding SER Nos:_ (see Quayle Action). Applicants are required to comply with requirements for patent application the specification.</li> <li>A n initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing."</li> <li>A hattement that the content of the paper and computer readable copies are the same are provide.</li> <li>A statement that the content of the paper and computer readable copies are the same are provide.</li> <li>A statement that the content of the paper and computer readable copies are the same are provide.</li> <li>A statement that the content of the paper and computer readable copies are</li></ul>	ant must file the items indicate hed to avoid abandonment ur ons of 37 CFR 1.136(a)).	ed below wil nder 35 U.S	thin the time period set the S.C. § 133 (extensions of t	e Office action to which the ime may be obtained unde
<ul> <li>In this application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. An attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), a of C 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rule notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).</li> <li>2. This application does not contain, as a separate part of the disclosure on paper copy, a "S Listing" as required by 37 C.F.R. 1.821(c).</li> <li>3. A copy of the "Sequence Listing" in computer readable form has not been submitted as red 37 C.F.R. 1.821(e).</li> <li>4. A copy of the "Sequence Listing" in computer readable form has been submitted. However content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."</li> <li>5. The computer readable form that has been filed with this application has been found to be readable form must be submitted as required by 37 C.F.R. 1.825(d).</li> <li>6. The paper copy of the "Sequence Listing" is not the same as the computer readable form or "Sequence Listing" as required by 37 C.F.R. 1.821(e).</li> <li>7. Other: the specification contains peptide sequences without the corresponding SEI (see Quayle Action). Applicants are required to comply with requirements for patent application taining amino acid sequence disclosure.</li> <li>pplicant Must Provide:</li> <li>An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing to the specification.</li> <li>A statement that the content of the paper and computer readable copies are the same are 125(d).</li> <li>requestions regarding compliance to these requirements, please contact: r Rules Interpretation, call (703) 308-4212 or 308-2923 tents.</li> </ul>				020 IOF the following reaso
<ul> <li>∠ 1. This application does not contain, as a separate part of the disclosure on paper copy, a "S Listing" as required by 37 C.F.R. 1.821(c).</li> <li>3. A copy of the "Sequence Listing" in computer readable form has not been submitted as red 37 C.F.R. 1.821(e).</li> <li>4. A copy of the "Sequence Listing" in computer readable form has been submitted. Howeve content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."</li> <li>5. The computer readable form that has been filed with this application has been found to be and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute of readable form must be submitted as required by 37 C.F.R. 1.825(d).</li> <li>6. The paper copy of the "Sequence Listing" is not the same as the computer readable from or "Sequence Listing" as required by 37 C.F.R. 1.821(e).</li> <li>∑ 7. Other: the specification contains peptide sequences without the corresponding SEQUENCE (see Quayle Action). Applicants are required to comply with requirements for patent applicant fully application.</li> <li>A ninitial or substitute computer readable form (CRF) copy of the "Sequence Listing".</li> <li>A ninitial or substitute paper copy of the "sequence Listing", as well as an amendment directing of the submitted as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.821(</li></ul>	nis application clearly fails to ntion is directed to the final ru 29 (May 15, 1990) If the off	comply with Itemaking n	h the requirements of 37 ( notice published at 55 FR	C.F.R. 1.821-1.825. Applic 18230 (May 1, 1990), and
<ul> <li>3. A copy of the "Sequence Listing" in computer readable form has not been submitted as red 37 C.F.R. 1.821(e).</li> <li>4. A copy of the "Sequence Listing" in computer readable form has been submitted. However content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."</li> <li>5. The computer readable form that has been filed with this application has been found to be and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute of the paper copy of the "Sequence Listing" is not the same as the computer readable from or "Sequence Listing" as required by 37 C.F.R. 1.825(d).</li> <li>6. The paper copy of the "Sequence Listing" is not the same as the computer readable from or "Sequence Listing" as required by 37 C.F.R. 1.821(e).</li> <li>∑ 7. Other: the specification contains peptide sequences without the corresponding SEC OS: (see Quayle Action). Applicants are required to comply with requirements for patent applicant and in a substitute computer readable form (CRF) copy of the "Sequence Listing".</li> <li>An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing of the specification.</li> <li>A statement that the content of the paper and computer readable copies are the same ar plicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d).</li> <li>r questions regarding compliance to these requirements, please contact: r Rules Interpretation, call (703) 308-4216 or (703) 308-2923</li> </ul>	his application does not conta	ain an a an	parate part of the disclosu	re on paper copy, a "Sequ
<ul> <li>A. A copy of the "Sequence Listing" in computer readable form has been submitted. However, content of the computer readable form does not comply with the requirements of 37 C.F.R. 1. 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."</li> <li>5. The computer readable form that has been filed with this application has been found to be and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute of readable form must be submitted as required by 37 C.F.R. 1.825(d).</li> <li>6. The paper copy of the "Sequence Listing" is not the same as the computer readable from or "Sequence Listing" as required by 37 C.F.R. 1.821(e).</li> <li>7. Other: the specification contains peptide sequences without the corresponding SECOS: _ (see Quayle Action). Applicants are required to comply with requirements for patent application table in the substitute computer readable form (CRF) copy of the "Sequence Listing".</li> <li>An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing to the specification.</li> <li>A statement that the content of the paper and computer readable copies are the same ar plicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.225(d).</li> <li>r questions regarding compliance to these requirements, please contact: r Rules Interpretation, call (703) 308-4216 or (703) 308-2923 tentin Software Prooram</li> </ul>				
<ul> <li>J 5. The computer readable form that has been filed with this application has been found to be and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute or readable form must be submitted as required by 37 C.F.R. 1.825(d).</li> <li>G. The paper copy of the "Sequence Listing" is not the same as the computer readable from or "Sequence Listing" as required by 37 C.F.R. 1.821(e).</li> <li>M 7. Other: the specification contains peptide sequences without the corresponding SECOS:_ (see Quayle Action). Applicants are required to comply with requirements for patent applicant applicant Must Provide:</li> <li>I An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".</li> <li>An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing of the specification.</li> <li>A statement that the content of the paper and computer readable copies are the same ar plicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.25(d).</li> <li>r questions regarding compliance to these requirements, please contact: r Rules Interpretation, call (703) 308-4216 or (703) 308-2923 tentin Software Program Support</li> </ul>	copy of the "Sequence Listin ent of the computer readable	g" in compu	uter readable form has bee	en submitted. However th
<ul> <li>6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of "Sequence Listing" as required by 37 C.F.R. 1.821(e).</li> <li>7. Other: the specification contains peptide sequences without the corresponding SECOS:_ (see Quayle Action). Applicants are required to comply with requirements for patent applicant applicant applicant sequence disclosure.</li> <li>pplicant Must Provide:</li> <li>An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".</li> <li>An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing of the specification.</li> <li>A statement that the content of the paper and computer readable copies are the same ar colicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.25(d).</li> <li>r questions regarding compliance to these requirements, please contact: r Rules Interpretation, call (703) 308-4216 or (703) 308-2923</li> <li>tentIn Software Program Support</li> </ul>	ne computer readable form the	at has beer	filed with this application	
<ul> <li>7. Other: the specification contains peptide sequences without the corresponding SEGOS: (see Quayle Action). Applicants are required to comply with requirements for patent applicant antaining amino acid sequence disclosure.</li> <li><b>pplicant Must Provide:</b> <ul> <li>An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".</li> <li>An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing to the specification.</li> <li>A statement that the content of the paper and computer readable copies are the same are policable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.25(d).</li> </ul> </li> <li>r questions regarding compliance to these requirements, please contact:         <ul> <li>r Rules Interpretation, call (703) 308-4216 or (703) 308-2923</li> <li>r CRF Submission Help, call (703) 308-4212 or 308-2923</li> </ul> </li> </ul>	e paper copy of the "Sequence			puter readable from of the
<ul> <li>an initial or substitute computer readable form (CRF) copy of the "Sequence Listing".</li> <li>An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".</li> <li>An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing of the specification.</li> <li>A statement that the content of the paper and computer readable copies are the same ar plicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d).</li> <li>Ar questions regarding compliance to these requirements, please contact: r Rules Interpretation, call (703) 308-4216 or (703) 308-2923</li> <li>r CRF Submission Help, call (703) 308-4212 or 308-2923</li> </ul>	7. Other: the specification	contains ne	entide sequences with a d	
<ul> <li>An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".</li> <li>An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing to the specification.</li> <li>A statement that the content of the paper and computer readable copies are the same ar plicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d).</li> <li>Or questions regarding compliance to these requirements, please contact: or Rules Interpretation, call (703) 308-4216 or (703) 308-2923 r CRF Submission Help, call (703) 308-4212 or 308-2923 tentIn Software Program Support</li> </ul>		are require	ed to comply with requirem	the corresponding SEQ IE lents for patent application
<ul> <li>An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".</li> <li>An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing to the specification.</li> <li>A statement that the content of the paper and computer readable copies are the same ar oplicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d).</li> <li>Or questions regarding compliance to these requirements, please contact: or Rules Interpretation, call (703) 308-4216 or (703) 308-2923 or CRF Submission Help, call (703) 308-4212 or 308-2923 of the source of the support.</li> </ul>		sure.		
<ul> <li>J An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing to the specification.</li> <li>A statement that the content of the paper and computer readable copies are the same ar oplicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d).</li> <li>Or questions regarding compliance to these requirements, please contact: or Rules Interpretation, call (703) 308-4216 or (703) 308-2923 or CRF Submission Help, call (703) 308-4212 or 308-2923 of CRF Submission Help, call (703) 308-4212 or 308-2923</li> </ul>	ial or substitute computer rea	dable form	(CRF) copy of the "Seque	nce Listing"
A statement that the content of the paper and computer readable copies are the same ar oplicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1. 825(d). Or questions regarding compliance to these requirements, please contact: or Rules Interpretation, call (703) 308-4216 or (703) 308-2923 or CRF Submission Help, call (703) 308-4212 or 308-2923	ial or substitute paper copy of ecification.	f the "Seque	ence Listing", as well as a	n amendment directing its
or questions regarding compliance to these requirements, please contact: or Rules Interpretation, call (703) 308-4216 or (703) 308-2923 or CRF Submission Help, call (703) 308-4212 or 308-2923 ItentIn Software Program Support	ement that the contact of the			
r CRF Submission Help, call (703) 308-4216 or (703) 308-2923 tentin Software Program Support	tions regarding complian	ice to the	se requirements place	
	Submission Help call (703	() 308-421		
Technical Assistance	nical Assistance	אכ		)

•